Unpacking Regenerative Medicines and Start-Up Funding with Luis Alvarez

Commentary
Video

Luis Alvarez, PhD, founder of Theradaptive, candidly discusses how his regenerative therapy start-up evolved and secured start-up funding.

Luis Alvarez, PhD, is the founder of Theradaptive, a biotech start-up focused on regenerative medicines. In this candid discussion with Grant Playter, associate editor, Luis discusses his company’s regenerative bone therapy, how it evolved from his experiences in Iraq, how Theradaptive secured funding in a lukewarm venture capital market, and more.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

Feliza Mirasol
March 25th 2025
Article

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.

Drug Solutions Podcast: Examining the State of Biopharma Investment

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
June 6th 2023
Podcast

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Shilpa Biologicals and mAbTree Biologics to Collaborate on Novel Immuno-Oncology Asset

Feliza Mirasol
March 18th 2025
Article

The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.

Women's Day poster with woman silhouette and fists inside in paper cut and copy space, 3D illustration. Girl face poster for feminism, independence, freedom, empowerment, activism for women rights | Image Credit: © AdriaVidal – stock.adobe.com

International Women’s Day 2025: Celebrating Women in Science

Felicity Thomas
March 8th 2025
Article

Supporting the prosperity of women in science fields benefits the bio/pharmaceutical industry.

Woman face silhouette in profile with group of multicultural and multiethnic women faces inside.Concept of racial equality anti-racism and a woman who gives voice to other women. Allyship | Image Credit: © melita – stock.adobe.com

International Women’s Day 2025: Improving Innovation in Industry

Felicity Thomas
March 8th 2025
Article

Gender diversity and equality in leadership positions have been shown to improve profitability and return on equity through greater innovation and more creative solutions.

Young female tech or scientist performs protein assay | Image Credit: © tilialucida - stock.adobe.com

Leaving STEM Skills on the Table

Susan Haigney
February 13th 2025
Article

Investing in STEM programs for girls in an education setting and then supporting women as they excel in their professional careers is key to ensuring that vital highly skilled personnel are not left behind.